Safety of use of low-dose IL-2 in SLE patients was also reported in two larger clinical trials.[48, 49] The first trial was a prospective, open-label study on thirty-eight SLE patients with active SLE who received three cycles of 1 million IU recombinant human IL-2 (rIL-2) subcutaneously every other day for 2 weeks followed by a two-week washout period. Here, IL2 is linked to systemic lupus erythematosus.